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Abstract
Background: The cell-cycle checkpoint kinase Chk1 is essential in mammalian cells due to its roles in controlling
processes such as DNA replication, mitosis and DNA-damage responses. Despite its paramount importance, how
Chk1 controls these functions remains unclear, mainly because very few Chk1 substrates have hitherto been
identified.
Results: Here, we combine a chemical genetics approach with high-resolution mass spectrometry to identify novel
Chk1 substrates and their phosphorylation sites. The list of targets produced reveals the potential impact of Chk1
function not only on processes where Chk1 was already known to be involved, but also on other key cellular
events such as transcription, RNA splicing and cell fate determination. In addition, we validate and explore the
phosphorylation of transcriptional co-repressor KAP1 Ser473 as a novel DNA-damage-induced Chk1 site.
Conclusions: By providing a substantial set of potential Chk1 substrates, we present opportunities for studying
unanticipated functions for Chk1 in controlling a wide range of cellular processes. We also refine the Chk1
consensus sequence, facilitating the future prediction of Chk1 target sites. In addition, our identification of KAP1
Ser473 phosphorylation as a robust readout for Chk1 activity could be used to explore the in vivo effects of Chk1
inhibitors that are being developed for clinical evaluation.
Background
Protein phosphorylation is an abundant post-transla-
tional modification that plays crucial roles in essentially
all cellular processes, including the DNA-damage
response (DDR). Key aspects of the DDR are the slow-
ing or stopping of cell cycle progression by DNA-
damage checkpoint pathways, which in part operate to
allow time for DNA repair to take place, and the induc-
tion of apoptosis if the damage is too severe. The main
DNA-damage signaling pathways are initiated by the
DNA-damage sensor protein kinases ATM (ataxia-telan-
giectasia mutated) and ATR (ataxia-telangiectasia and
Rad3 related). In addition to them cooperating with the
related kinase DNA-PK to phosphorylate various pro-
teins at DNA-damage sites, such as histone H2AX (to
yield a phosphorylated species termed gH2AX), ATM
and ATR phosphorylate and activate the downstream
effector checkpoint kinases Chk2 and Chk1, respectively
(for recent reviews, see [1,2]). Notably, a third check-
point effector kinase has recently been shown to func-
tion downstream of ATM/ATR, working in parallel to
Chk1 [3]. This p38MAPK/MAPKAP-K2 (MK2) complex
is activated in response to DNA-damaging agents such
as ultraviolet light and shares several checkpoint-rele-
vant substrates with Chk1. The degree of overlap
between Chk1, Chk2 and MK2 is not known, but it has
been suggested that MK2 acts predominantly in the
cytoplasm in the later phases of the DDR (reviewed in
[4]). The importance of the DDR is underscored by the
fact that failure to activate DNA-damage checkpoints
increases genomic instability and can lead to a range of
diseases [1]. For instance, people or animals with defects
in the ATM/Chk2 pathway display heightened predispo-
sition to cancer, although cells deficient in ATM or
Chk2 are otherwise viable [5,6]. By contrast, ATR and
Chk1 are essential for mammalian cell viability, and
knockout mice for these proteins display embryonic
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any medium, provided the original work is properly cited.lethality [7-10]. The essential roles of Chk1 in the cell
are still unclear, mainly because very few substrates of
Chk1 have been identified to date.
As hundreds of protein kinases are encoded by the
human genome, all of which use ATP as their co-factor,
and because tens-of-thousands of potential phosphoryla-
tion sites have been identified in human proteins
[11,12], it has been challenging to define kinase-sub-
strate relationships. Identification of such pairs is usually
based on the researcher making an educated guess, fol-
lowed by in vitro kinase assays and in vivo confirmation
with phospho-specific antibodies. The identity of the
kinase is then further confirmed by the use of specific
kinase inhibitors and/or short-interfering RNA (siRNA)-
mediated kinase depletion. Screening for large numbers
of protein kinase substrates has proven more difficult,
although recent antibody-based screens have identified
hundreds of putative ATM and ATR substrates [13,14].
As such screenings require the previous identification of
sites of substrate phosphorylation and corresponding
antibodies that specifically recognize these phosphory-
lated motifs, these approaches are unfortunately not fea-
sible for kinases such as Chk1 that have few known
targets, that share phosphorylation motifs with other
kinases and/or lack a highly specific target motif.
Chemical genetics employs small-molecule modulators
of protein and nucleic acid activities to elucidate cellular
functions of their targets. Notably, Shokat and co-work-
ers [15] have developed a chemical-genetics system to
modulate the activity of a protein kinase by mutating an
amino acid residue in its ATP-binding pocket (the ‘gate-
keeper’ residue), allowing the resulting kinase - often
called an analogue-sensitive (as)-kinase - to accommo-
date a bulky ATP analogue. This modified ATP-binding
pocket allows the specific inhibition of the as-kinase in
vivo by using specific cell-membrane-permeable, non-
hydrolysable ATP analogues. More recently, new meth-
ods to identify in vitro substrates of as-kinases have
been developed that involve the use of a hydrolysable
and labeled ATP analogue in cell extracts. This latter
approach has been successfully applied to the identifica-
tion of new substrates of protein kinases such as CDK1/
CyclinB, CDK7, and CDK2/CyclinA [16-18]. Here, by
applying this technique to Chk1, we identify 268 phos-
phorylation sites in 171 proteins, thus providing for the
first time an unbiased list of putative Chk1 substrates.
Results
Production of an analogue-sensitive Chk1
Amino acid alignment of the ATP-binding region of
Chk1 with those of protein kinases for which as versions
have been already successfully generated suggested that
Leu84 should behave as the gatekeeper residue (Figure
1a). Modeling ATP-analogue binding in the ATP-
binding pocket of Chk1 further supported this idea, as it
indicated that, while the bulky benzyl group of an ATP
analogue would not fit inside the wild type Chk1 ATP-
binding site, it probably could be accommodated if
Leu84 was mutated to a smaller residue such as glycine
(Figure 1b). Accordingly, we mutated Leu84 to alanine
or glycine and then carried out in vitro kinase assays
w i t ht h e s ea n dw i l dt y p eC h k 1i nt h ep r e s e n c eo ft h e
known Chk1 substrate Cdc25A. Importantly, wild type
and both mutated versions of Chk1 were able to use
ATP, as evidenced by them mediating Cdc25A phos-
phorylation on Ser123 as detected by western blotting
w i t haS e r 1 2 3p h o s p h o - s p e c i f i ca n t i b o d y[ 1 9 ]( F i g u r e
1c). By contrast, only the leucine-to-glycine gatekeeper-
mutated Chk1 derivative Chk1-L84G phosphorylated
Cdc25A in the presence of the ATP analogue N6-benzyl
(N6B)-ATP (Figure 1c). The induction of Cdc25A phos-
phorylation in such assays paralleled that of Chk1
autophosphorylation, as evidenced by the appearance of
a slower-migrating Chk1 band on the western blots (Fig-
ure 1c, lower panels, lanes 4 to 6 and 9). We did not
characterize this Chk1 autophosphorylation further but
noted that, while Chk1 is phosphorylated on Ser317 and
Ser345 by ATR after DNA damage and these phosphor-
ylations are thought to be important for Chk1 kinase
activity [9,20], both Ser317 and Ser345 became phos-
phorylated upon incubating recombinant Chk1 in the
presence of ATP (Figure 1d). Collectively, these data
suggested that Chk1 autophosphorylation in vitro can
mimic ATR activation of Chk1, and more importantly,
revealed that Chk1-L84G serves as an active as version
of Chk1.
as-Chk1 identifies new in vitro substrates and
phosphorylation sites
A recent, elegant method developed to identify sub-
strates of an as-kinase involves the use of an ATP analo-
gue carrying a thio-phosphate group [16]. In this
approach, once the kinase reaction is performed with
the as-kinase and its potential substrates in the presence
of the ATP analogue, proteins are digested by trypsin
(Figure 2a, step 1) and thio-phosphorylated peptides are
specifically isolated via their specific covalent binding to
iodo-acetyl agarose beads. After several stringent and
extensive washes, the thio-phosphorylated peptides are
then specifically eluted with an oxidizing agent that at
t h es a m et i m ec o n v e r t st h e mi n t os t a n d a r dp h o s p h o -
peptides (Figure 2a, step 2) that can subsequently be
analyzed by mass spectrometry (Figure 2a, step 3).
Firstly, to test whether as-Chk1 could also use a thio-
phosphate ATP analogue (N6B-ATPgS), we carried out
an in vitro kinase assay. Importantly, as shown in Figure
2b, as-Chk1 efficiently autophosphorylated in the pre-
sence of N6B-ATPgS, as revealed both by the generation
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and by direct detection of the auto-modified protein
with an antibody specific to the thio-phosphate ester
moiety.
As an approach to identify Chk1 target proteins, we
next carried out a kinase assay with as-Chk1 and N6B-
ATPgS in the presence of human HeLa cell nuclear
extract. To control for the possibility of background sig-
nals arising from the hypothetical use of N6B-ATPgSb y
endogenous kinases, we carried out an equivalent reac-
tion without the addition of recombinant as-Chk1. Both
samples were then processed the same way (Figure 2a)
and all phospho-sites identified in both the control reac-
tion (without as-kinase) and the as-kinase reaction were
discarded. This analysis thus produced a list of 268
phosphorylation sites in 171 proteins that were only
generated in the presence of as-Chk1 (Additional file 1).
Notably, most of the identified phosphorylation sites
also occur in vivo, as revealed by 62% of them existing
in the two protein phosphorylation databases Phospho-
Site [11] and PHOSIDA [12] (Figure 2c).
As shown in Figure 2d, the proteins identified in the
screen as Chk1 targets are involved in a variety of biolo-
gical processes, the majority of them playing roles in
nucleic acid metabolism. Further analysis of this sub-
group revealed that most of the proteins are involved in
either transcription or RNA processing (Figure 2d), in
agreement with recent data indicating close linkages
between genome stability and RNA synthesis/metabo-
lism [21-23]. Furthermore, although our screen was not
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Figure 1 Producing a Chk1 kinase derivative able to use N6-benzyl(N6B)-ATP. (a) Amino acid alignment of ATP-binding pockets of human
Chk1, Saccharomyces cerevisiae Cdc28, human Cdk2 and c-Abl, and viral v-Src. The identified gatekeeper amino acids are highlighted. (b) ATP-
binding pocket of Chk1 (based on PDB entry 1IA8) showing the position of the gatekeeper residue Leu84 (i), the L84G mutation (ii), or the L84G
mutated ATP-binding pocket accommodating N6B-adenosine (iii). Models were drawn by Chimera software [60]. (c) Chk1-L84G can use ATP
analogues. In vitro kinase assay using wild type (WT) or gatekeeper mutant versions (L84A, L84G) of Chk1 in the presence of ATP or N6B-ATP.
Active kinases phosphorylate Cdc25A on Ser123 as detected by phospho-specific antibody. Chk1 mobility shift due to autophosphorylation is
indicated by arrows; 0.5 μg of each recombinant protein was used. (d) Recombinant WT Chk1 autophosphorylates on Ser345 and Ser317 as
detected by phospho-specific antibodies; 1 μg of recombinant Chk1 was used.
Blasius et al. Genome Biology 2011, 12:R78
http://genomebiology.com/content/12/8/R78
Page 3 of 14(b)
(e)
Known in vivo
(162)
Sites (268)
Substrates
(171)
DDR link
(68)
Prot
(d)
(a)
CHK1
CHK1 TPE
N6B-ATPGS - +
(c)
(f)
10
5
-5
-10
5
0
.
0
=
e
u
l
a
v
P
e
g
n
a
h
c
d
l
o
F
15
-5
-10
5
0
.
0
=
e
u
l
a
v
P
e
g
n
a
h
c
d
l
o
F
7.5
(g)
Misc
prot
ein syn
ellaneous (8%)
Protein modification/
ein shuttling (9%)
thesis/ folding/
degradation (6%)
Development
(3%) Cell morphology/
cytoskeleton (6%)
Cell cycle/
cytokinesis (9%)
Nucleic acid
metabolism (39%) Transcription
(38%)
RNA processing (33%)
DNA replication/
recombination/repair (23%)
Chromatin architecture (6%)
Unknown (20%)
1. Kinase assay and trypsin digest
+ N6B-ATP
nuclear extract
+ as - Chk1
trypsin digest
covalent binding of 
thio-phosphates to beads
stringent 
washes
specific elution 
and conversion
3. Identification of phospho-peptides by mass spectrometry
2. Purification of thio-phosphopeptides
Figure 2 Bioinformatic analyses of potential Chk1 substrates based on phospho-peptides identified by mass spectrometry. (a)
Schematic for in vitro labeling and identification of Chk1 substrates. (b) as-Chk1 uses N6B-ATPgS as detected by antibodies recognizing thio-
phosphorylation (thio-phosphate ester (TPE) moiety). (c) Euler diagram depicting the proportion of phospho-sites identified known to occur in
vivo [11,12]. (d) Classification of identified Chk1 substrates based on biological processes (Gene Ontology Consortium). Proteins involved in
nucleic acid metabolism were further classified. (e) Euler diagram depicting the proportion of proteins found in this screen with links with the
DNA-damage response (DDR; comparison with [13,14,21,23-25]). (f) Frequencies of amino acids surrounding phospho-sites identified in our
screen. The x-axis represents the sequence window, with the phosphorylated residue in the middle. Amino acid size depicts fold enrichment
(positive, above y-axis) or under-representation (negative, below y-axis) after normalization to amino acid occurrences in the human proteome.
Amino acid colors: black, hydrophobic; blue, basic; red, acidic; green, polar; purple, ester. Residues shown in pink were never found in a given
position. Note that phospho-peptides containing cysteine were not recovered due to methodological limitations [16]. Diagrams were made with
IceLogo software [61]. (g) IceLogo for phospho-peptides with R/K at -3.
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phosphorylations by Chk1, almost 40% of the substrates
we identified overlapped with those identified in recently
published DDR-focused phospho-proteomic screens
[13,14,21,23-25] (Figure 2e).
Some protein kinases target a well-defined consensus
amino acid sequence, allowing the prediction of poten-
tial substrates. A clear Chk1 consensus has not been
established so far due to the limited number of its
known substrates, although approaches using peptide
libraries for in vitro kinase assays have suggested a gen-
eral preference for an arginine residue in the -3 position
and a hydrophobic residue at -5 [26,27]. However, sev-
eral exceptions to this consensus have been observed in
vitro and in vivo,a si st h ec a s ef o rS e r 2 0o fp 5 3[ 2 8 , 2 9 ]
and Thr916 of Claspin [30]. To establish target-
sequence preferences for Chk1 arising in our screen, we
defined the frequency values for amino acid residues
surrounding the 268 identified phosphorylation sites and
then normalized these values to the different frequencies
of each amino acid in the human proteome. As shown
in Figure 2f, this allowed us to assess, at each position
relative to the phosphorylation site, whether a particular
amino acid was statistically over-represented (above the
central line), under-represented (below the line), or not
significantly selected one way or the other (not indi-
cated). Strikingly, this revealed that Chk1 targets arising
in our screen displayed an overall bias towards the pre-
sence of basic residues amino-terminal to the phos-
phorylated site. While this included a strong over-
representation of Arg and Lys at position -3, as pre-
viously reported [26,27], we observed little selection for
hydrophobic residues at -5 (Figure 2f). Additional, albeit
weaker, over-representations included those for Ser and
negatively charged (Glu/Asp) residues between positions
+2 and +5. Notably, in addition to our data indicating
positive amino acid residue selections within the Chk1
motif, clear amino acid under-representations were also
evident at certain positions (Figure 2f). Perhaps surpris-
ingly given its partially basic character, His was not
over-represented in the region amino-terminal to the
phosphorylation site and was, in fact, strongly disfavored
at position -5. Moreover, acidic residues were strongly
disfavored at position -2, while Met was clearly disfa-
vored at position -1. Under-representation of Met,
together with other bulky, generally hydrophobic resi-
dues, was also observed carboxy-terminal to the phos-
phorylated residue, particularly at positions +2 to +4.
Yet further amino acid residue biases became evident
when we analyzed subsets of Chk1 target sequences. A
prime example of this is provided when we focused on
the set of 120 Chk1-target phospho-peptides displaying a
basic residue (Lys or Arg) at position -3 (Figure 2g). In
this set of phospho-peptides, slight over-representations
of hydrophobic residues at position -5, -1, and +4 were
observed along with a slight preference for Arg/Lys resi-
dues at -4. More striking, however, was the pattern of
under-represented amino acid residues, which included
Thr at -1 and basic residues at +2 and +3. Also clearly
under-represented were acidic residues at -2 and -4 sur-
rounding the basic residue at -3. Intriguingly, additional
differences in amino acid representation profiles were
apparent when the set of Chk1 targets containing Arg/
Lys at -3 was split into those containing phospho-Ser or
phospho-Thr. For instance, while there was a clear
enrichment of hydrophobic residues -5 to phospho-Thr,
this was not the case for targets containing phospho-Ser
(Additional file 2). Taken together, these results indicate
that substrate sequence preferences for Chk1 are com-
plex, with both positive and negative selections being evi-
dent. Furthermore, they indicate that, for Chk1
substrates bearing Arg/Lys at -3, the preferred consensus
sequence can be denoted R/K-R/K-d/e-t-S*/T*-X-r/k-r
(applying a cut-off of five-fold enrichment), where phos-
phorylated residues are indicated by asterisks, preferred
amino acids are in capital letters, disfavored ones are in
lower case and × indicates no preference.
KAP1-Ser473 phosphorylation is DNA-damage induced
Through identifying phosphorylation sites arising from
our screen that conformed well to the target motifs
defined above, that were relatively conserved throughout
evolution and that occurred in vivo as shown by their
inclusion in the PhosphoSite and/or PHOSIDA data-
bases [11,12], we derived a shortlist of Chk1 targets for
further characterization (Table 1). Of these, we first
focused on Ser473 of the human transcriptional co-
repressor KAP1 (Krüppel-associated box domain-asso-
ciated protein 1; also known as TRIM28 or Tif1b),
which has previously been linked to the DDR [31].
KAP1 is an essential protein with a role in early mam-
malian development [32] and is phosphorylated on
Ser824 by ATM in response to DNA damage [31]. This
ATM-dependent phosphorylation is believed to release
KAP1 from its usual chromatin-bound state, an event
that triggers chromatin relaxation and promotes DNA
double-strand break (DSB) repair within heterochroma-
tin [31,33,34]. Notably, Ser473 lies just amino-terminal
to the conserved heterochromatin protein 1 (HP1) box
of KAP1 that mediates its interaction with the hetero-
chromatin-associated protein HP1 (Figure 3a). Further-
more, while the motif containing human KAP1 Ser473
is not present in the KAP1-related proteins Tif1a and
Tif1g, it is well conserved in vertebrate KAP1 counter-
parts, including those of mouse and Xenopus, suggesting
that it is likely to be important functionally (Figure 3a;
note that, like Ser473 itself, the Arg at -3 is particularly
highly conserved).
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Protein name Gene name Phospho-site identified
Alpha-adducin ADD1 KKFRTPSFLKKSK (S726)
Rho guanine nucleotide exchange factor 2 ARHGEF2 GLRRILSQSTDSL (S172)
Uncharacterized protein C10orf47 C10orf47 SSSRSRSFTLDDE (S43)
Calmodulin-regulated spectrin-associated protein 2 CAMSAP1L1 GITRSISNEGLTL (S464)
Coiled-coil domain-containing protein 49 CCDC49 GYTRKLSAEELER (S337)
Cell division cycle 2-like protein kinase 5 CDC2L5 SRSRHSSISPSTL (S437)
RNA polymerase-associated protein CTR9 homolog CTR9 RPRRQRSDQDSDS (S1081)
Flap endonuclease 1 FEN1 VLMRHLTASEAKK (T195)
Golgin subfamily A member 4 GOLGA4 LQLRVPSVESLFR (S71)
General transcription factor 3C polypeptide 1 GTF3C1 RLVRNLSEEGLLR (S667)
Zinc finger protein 40 HIVEP1 SSKRMLSPANSLD (S1749)
Heterogeneous nuclear ribonucleoprotein M HNRNPM GMDRVGSEIERMG (S432)
Importin subunit alpha-2 KPNA2 LKRRNVSSFPDDA (S54)
LIM domain only protein 7 LMO7 IMRRGESLDNLDS (S1510)
Microtubule-associated protein 4 MAP4 RLSRLATNTSAPD (T925)
Matrin-3 MATR3 QLKRRRTEEGPTL (T150)
FDDRGPSLNPVLD (S195)
Myb-binding protein 1A MYBBP1A LVIRSPSLLQSGA (S1310)
Probable E3 ubiquitin-protein ligase MYCBP2 MYCBP2 VFQRSYSVVASEY (S3440)
Nance-Horan syndrome protein NHS KLRRRKTISGIPR (T380)
Nuclear pore complex protein Nup153 NUP153 DAKRIPSIVSSPL (S330)
O-GlcNAc transferase subunit p110 OGT PTKRMLSFQGLAE (S20)
Oxysterol-binding protein-related protein 11 OSBPL11 ISQRRPSQNAISF (S189)
PHD finger protein 8 PHF8 EGTRVASIETGLA (S904)
Pleiotropic regulator 1 PLRG1 KIQRMPSESAAQS (S119)
Protein phosphatase methylesterase 1 PPME1 HLGRLPSRPPLPG (S15)
Protor-1 PROTOR1 LLRRSRSGDVLAK (S240)
RNA-binding protein 7 RBM7 IIQRSFSSPENFQ (S136)
RNA-binding protein 14 RBM14 SDYRRLSESQLSF (S618)
SFRRSPTKSSLDY (T629)
Telomere-associated protein RIF1 RIF1 NKVRRVSFADPIY (S2205)
60S ribosomal protein L19 RPL19 PQKRLASSVLRCG (S12)
Sentrin-specific protease 2 SENP2 LLRRKVSIIETKE (S344)
Paired amphipathic helix protein Sin3a SIN3A QIRRHPTGTTPPV (T432)
Serine/arginine repetitive matrix protein 2 SRRM2 QTPRPRSRSPSSP (S1497)
PRPRSRSPSSPEL (S1499)
TBC1 domain family member 4 TBC1D4 VIQRHLSSLTDNE (S485)
MRGRLGSVDSFER (S588)
Treslin (C15orf42) TICRR ALIRHKSIAEVSQ (S865)
SVQRVHSFQQDKS (S1045)
Transcription intermediary factor 1-beta, KAP1 TRIM28 GVKRSRSGEGEVS (S473)
TRIP12 protein TRIP12 GLARAASKDTISN (S1078)
ATP-dependent DNA helicase 2 subunit 1, Ku70 XRCC6 FTYRSDSFENPVL (S477)
Nuclear-interacting partner of ALK ZC3HC1 FFSRVETFSSLKW (T84)
Zinc finger protein 395 ZNF395 SPVRSRSLSFSEP (S447)
Proteins in this list were selected based on the following criteria: (i) phosphorylation site conserved from human to Xenopus laevis; (ii) presence of an arginine
residue at position -3 with respect to the phosphorylation site; (iii) phospho-site known to occur in vivo (PhosphoSite and Phosida databases [11,12]). For a
detailed list of all mass spectrometry results, see Additional file 1.
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Figure 3 KAP1 Ser473 phosphorylation upon DNA damage. (a) Schematic of human KAP1; known domains are highlighted in color and
labeled with bounding amino acid residue numbers. DNA-damage-induced Ser824 phosphorylation site is marked in red. Inset shows an
alignment of the region surrounding Ser473 of human [Swissprot: Q13263], mouse [Swissprot: Q62318], and Xenopus laevis KAP1 [Swissprot:
Q2TAS5] with the phosphorylated residue highlighted in yellow. (b) KAP1 phospho-Ser473 is detected on western blot after treating cells with
various DNA-damaging agents. U2OS cells were not treated (NT) or treated with 1 μM camptothecin (CPT) for 2 h, 5 μM etoposide (ETP) for 2 h,
2 mM hydroxyurea (HU) for 12 h, 10 Gy of ionizing radiation (IR) 1 h before harvesting, 60 μg/ml phleomycin (PHL) for 1 h, or 10 J/m
2 of
ultraviolet light (UV) 1 h before harvesting. (c) Antibodies against KAP1 phospho-Ser473 are specific in immunofluorescence. U2OS cells were
transfected with siLuc or siKAP1, irradiated with 20 Gy IR and fixed 2 h afterwards. (d) Specificity of KAP1 phospho-Ser473 antibody by western
blotting. U2OS cells stably expressing wild type (wt), S473A, S473D, or S824A versions of GFP-KAP1 were treated with 5 μM etoposide (ETP) for 4
h. Phosphorylation of endogenous KAP1 on Ser824 was used as a DNA-damage readout.
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lated in response to DNA damage, we used a commer-
cial phospho-specific antibody raised against this site
(see Materials and methods). Through western immuno-
blot analyses, we found that KAP1 detection with this
antibody was induced when cells were treated with
various DNA-damaging agents, including the DNA
topoisomerase I inhibitor camptothecin, the DNA topoi-
somerase II inhibitor etoposide, the DNA-replication
inhibitor hydroxyurea, ionizing radiation (IR), the radio-
mimetic drug bleomycin and ultra-violet light (Figure
3b). In addition, while this antibody only weakly stained
untreated cells, exposure to IR produced pan-nuclear
immunostaining in control cells but not in cells treated
with siRNA directed against KAP1 (Figure 3c).
To further verify the specificity of the phospho-KAP1
Ser473 antibody, we created human U2OS cell lines sta-
bly expressing wild type KAP1, a non-phosphorylatable
Ser473-to-Ala mutant (S473A) or a potential phospho-
mimicking Ser473-to-Asp derivative (S473D). Impor-
tantly, while the antibody detected wild type KAP1 from
cells that had been treated with etoposide, it did not
detect either KAP1-S473A or KAP1-S473D after such
treatment (Figure 3d). In parallel with these analyses, we
assessed ATM-mediated phosphorylation of KAP1 on
Ser824 and also employed a U2OS cell line stably
expressing a KAP1 derivative in which Ser824 was
mutated to Ala (S824A). This revealed that phosphoryla-
tions of Ser473 and Ser824 are independent events, as
no difference in the phosphorylation of one site was
observed when the other site was mutated (Figure 3d).
Moreover, the DNA-damage induction profiles of the
two sites were also markedly different, with Ser824
being mainly induced by DSB-inducing agents, while
Ser473 was generated at similar levels by all DNA-
damaging treatments employed, including low doses of
hydroxyurea and ultraviolet light that produce few or no
DSBs (Figure 3b). Collectively, these data indicated that
KAP1 Ser473 is phosphorylated when cells are treated
with a wide variety of DNA-damaging agents.
KAP1 Ser-473 phosphorylation is mediated by Chk1 and
Chk2
To explore the factor-dependencies of KAP1 Ser473
phosphorylation, we carried out experiments with the
selective Chk1/Chk2 inhibitor AZD7762 [35], the speci-
fic ATM inhibitor KU55933 [36], or caffeine at a con-
centration that inhibits both ATM and ATR [37]. This
revealed that phosphorylation of KAP1 Ser473 in
response to etoposide or IR was essentially abolished
when cells were incubated with AZD7762, indicating
that KAP1 Ser473 is a Chk1/2 target (Figures 4a-c). By
contrast, and consistent with our data indicating that
phosphorylation of KAP1 Ser473 and Ser824 operate
independently (Figure 3d), Chk1/2 inhibition by
AZD7762 did not diminish KAP1 Ser824 phosphoryla-
tion, which was only decreased upon ATM inhibition
(Figure 4a). Furthermore, KAP1 Ser473 phosphorylation
was reduced by caffeine and KU55933, in line with
Chk1 being targeted by ATR in response to etoposide
treatment in a manner that is promoted by ATM [38]
(Figure 4a; note that Chk1 Ser345 phosphorylation upon
etoposide treatment was also inhibited by caffeine and
by ATM inhibition). Similar to the effects observed for
etoposide, IR-induced KAP1 Ser473 phosphorylation
was also virtually abolished by AZD7762 treatment (Fig-
ure 4b). As expected, AZD7762 did not prevent ATM-
mediated phosphorylation of Chk2 on Thr68 but, in line
with the known checkpoint functions of Chk1, it abro-
gated DNA-damage-induced G2/M cell cycle arrest, as
evidenced by it preventing the diminution of mitotic
histone H3 Ser10 phosphorylation upon IR treatment
(Figure 4b).
Because AZD7762 inhibits both Chk1 and Chk2 [35],
and as previous work has indicated that Chk1 and Chk2
have overlapping substrate specificities [39], we
employed siRNA-depletionm e t h o d st od e t e r m i n e
whether both Chk1 and Chk2 can target KAP1 Ser473.
As shown in Figure 4d, Chk1 depletion but not Chk2
depletion abolished KAP1 Ser473 phosphorylation
induced by aphidicolin, which inhibits replicative DNA
polymerases and activates the ATR/Chk1 pathway in S-
phase cells [40] (note that gH2AX staining indicates that
DNA damage still occurred in Chk1-depleted cells). By
contrast, when we induced DNA damage by IR, KAP1
Ser473 phosphorylation was only reduced slightly by
Chk1 depletion but was reduced much more substan-
tially upon Chk2 depletion (Figure 4e; note that full
abrogation of KAP1 Ser473 phosphorylation after IR
required co-depletion of Chk1 and Chk2). These results
therefore indicated that both Chk1 and Chk2 can target
KAP1 Ser473, and are in agreement with IR triggering
both the ATM/Chk2 and ATR/Chk1 pathways [38].
Various proteins involved in DNA-damage signaling
and repair form discrete nuclear foci upon IR, marking
sites where DNA damage has occurred [41]. This is not
t h ec a s e ,h o w e v e r ,f o rK A P 1o rK A P 1p h o s p h o - S e r 8 2 4 ,
which are evenly distributed throughout the nucleo-
plasm after DNA damage [31]. Similarly, we observed
pan-nuclear staining with the KAP1 phospho-Ser473
antibody (Figures 3c and 4c-e). To provide a more
detailed analysis of Ser473 phosphorylation dynamics,
we used laser micro-irradiation to induce localized DNA
damage [41]. While such an approach has shown that
KAP1 is transiently recruited to sites of damage, where
it is phosphorylated on Ser824 and then released [31],
we observed neither association nor exclusion of KAP1
phospho-Ser473 from sites of laser micro-irradiation
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Page 8 of 14Figure 4 KAP1 phospho-Ser473 after DNA damage is Chk1- and Chk2-dependent. (a) Etoposide-induced KAP1 Ser473 phosphorylation is
abolished by Chk1/Chk2 inhibition and reduced upon ATM inhibition. U2OS cells were untreated or treated with 5 μM etoposide (ETP) for 4 h
in the presence or absence of KU55933 (ATMi), caffeine (Caff), or AZD7762 (AZD). (b) KAP1 phospho-Ser473 induction after 20 Gy of IR is
abolished by AZD7762 (the drug was not removed during the recovery time). Chk2 phospho-Thr68 was used as readout of DNA damage and
histone H3 phospho-Ser10 was used as readout for the G2/M checkpoint. (c) AZD7762 decreases KAP1 phospho-Ser473 on immunofluorescence;
U2OS cells were treated as in (b). (d) KAP1 Ser473 is targeted by Chk1. U2OS cells were transfected with either siLuc, siChk1, siChk2, or both
siChk1 and siChk2, then treated with 10 μM aphidicolin for 1 h. (e) KAP1 Ser473 is targeted by Chk2. U2OS cells were transfected as in (d) and
treated as in (b). (f) KAP1 phospho-Ser473 is neither recruited nor excluded from laser-induced DNA-damage sites. Cells were fixed 5, 10 or 30
minutes after micro-irradiation.
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Page 9 of 14(Figure 4f). These data suggested that KAP1 Ser473
phosphorylation by Chk1 and Chk2 does not take place
predominantly at sites of DNA damage, and are consis-
tent with previous work indicating that, following their
DNA-damage-localized phosphorylation and activation
by ATR and ATM, Chk1 and Chk2 dissociate from
chromatin to phosphorylate their substrates [42,43].
We carried out various functional studies to ascribe a
specific function to KAP1 Ser473. For example, we
found that mutating Ser473 did not affect KAP1 phos-
phorylation on Ser824 (Figure 3d) or KAP1 SUMOyla-
tion (Additional file 3), which has been implicated in
transcriptional silencing [44]. Furthermore, in line with
previous findings [31], we found that DNA damage did
not perceptibly change KAP1 interactions with its bind-
ing partners SETDB1, HDAC1 and MDM2 (Additional
file 4). Importantly, we discovered that the recently
reported serum induction of KAP1 Ser473 phosphoryla-
tion [45] was not affected by AZD7762 (Figure S4a in
Additional file 5), indicating that another kinase(s) tar-
gets this site upon serum stimulation. In line with this
and the fact that we observed similar levels of IR-
induced KAP1 Ser473 phosphorylation in all cells of an
asynchronously growing population (Figures 3c and 4c),
we found no correlation between DNA-damage-induced
KAP1 Ser473 phosphorylation and cell-cycle stage (Fig-
ure S4b in Additional file 5). Moreover, although a
recent report [45] concluded that cell-cycle regulated
KAP1 phosphorylation on Ser473 controls the interac-
tion between KAP1 and HP1b, we observed no effect of
mutating Ser473 on the binding of KAP1 to HP1 (Figure
S4c in Additional file 5; as shown in Figure S4d in Addi-
tional file 5 there was also no apparent relationship
between KAP1 Ser473 phosphorylation and chromatin
status). We therefore conclude that the effects of Ser473
phosphorylation are too subtle to be detected by existing
assays, or that this phosphorylation site regulates as yet
undefined KAP1 functions.
Discussion
We have used a chemical genetics approach, employing
am u t a t e das-Chk1 derivative that can utilize the ATP
analogue N6B-ATPgS, to identify proteins that can serve
as direct substrates for Chk1. Through defining a con-
siderable number of Chk1 phosphorylation sites using
this technique, we have further refined the Chk1 con-
sensus sequence. Strikingly, our analyses indicate that,
in addition to the over-representation of certain amino
acid residues at particular positions within the Chk1 tar-
get motif, there are also other residues that are mark-
edly under-represented in certain positions. Thus, we
are led to the overall target consensus motif for Chk1
being R/K-R/K-d/e-t-S*/T*-X-r/k-r, where capital and
lower-case letters reflect selection and counter-selection,
respectively. Notably, through further investigations into
various subsets of Chk1 targets, we have found that the
‘rules’ for Chk1 target recognition cannot be explained
simply on the basis of selecting or counter-selecting for
certain residues at specific positions. Instead, more com-
plex, context-dependent selections also seem to operate,
and it appears that more than one class of target motif
may exist, perhaps pointing towards Chk1 using adaptor
proteins to recognize its substrates. It should be possible
to explore these ideas by mutational analyses and by
structural studies of Chk1 in association with various
types of target sequence, and it will be intriguing to see
whether similar situations exist for other protein
kinases.
In addition to identifying and validating KAP1 as a
Chk1 target, our screen identified several other proteins
involved in DNA replication and repair, including Fen1,
Rif1, TICRR/Treslin and Ku70 (Table 1). It will be inter-
esting, therefore, to investigate the potential effects of
Chk1 on the activities of such factors. Notably, however,
a considerable proportion of the Chk1 substrates we
identified have been assigned roles in transcription and/
or RNA processing, cellular functions that are being
increasingly linked to the control of genome stability
[46]. In line with this, we found that several of the
newly identified Chk1 substrates functionally clustered
around transcription factor ZNF143, which is known to
control expression of DNA repair- and cell-cycle-related
genes [47,48], and around SARNP, a protein linked to
transcription and RNA export with a suggested role in
cell growth and carcinogenesis [49,50] (Additional file
6). Further work will be required to validate such factors
as true Chk1 substrates and determine whether and how
Chk1 - and possibly Chk2 and MK2, which have similar
consensus motifs to Chk1 [4] - regulate the events that
they control. Finally, we note that, because Chk1 inhibi-
tors are being assessed as anti-cancer agents [51], under-
standing the repertoire and functional consequences of
Chk1-mediated phosphorylations might suggest how
Chk1 inhibitors can be best exploited clinically. In order
to most effectively develop Chk1 inhibitors, it will be
necessary to have a robust and accurate readout of
Chk1 activity. While previous work has mainly used
phosphorylation of Chk1 itself on Ser345 as a biomarker
for Chk1 inhibition, there are two limitations to this:
first, Chk1 Ser345 phosphorylation is only clearly
detected after prolonged treatments with Chk1 inhibi-
t o r s ;a n ds e c o n d ,S e r 3 4 5p h o s phorylation is an indirect
readout of Chk1 inhibition as it appears to measure the
hyper-activation of ATR that occurs when Chk1 is
inhibited [52]. Our work highlights the potential for
measuring KAP1 Ser473 phosphorylation as an alterna-
tive, more direct way of monitoring Chk1 activity and
its inhibition.
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We have described the results of a screen for novel
Chk1 substrates. The approach used employed an analo-
gue-sensitive mutant of Chk1 that can directly label sub-
strates in cell extracts by it using a thio-phosphate-
bearing ATP analogue. Thus, we have identified 268
phosphorylation sites in 171 proteins. Based on these
results, we have refined the preferred Chk1 target phos-
phorylation motif. Furthermore, as proof-of-concept for
the screening approach, we established that one of the
sites identified, Ser473 on the transcriptional co-repres-
sor KAP1, indeed serves as a DNA-damage-responsive
Chk1/Chk2 target in cells. In addition to providing clues
into how Chk1 may control diverse cellular functions
and defining a marker of potential utility in evaluating
t h ee f f e c t so fC h k 1i n h i b i t o r sin vivo, our data provide
additional resources that should be valuable for future
research.
Materials and methods
DNA constructs and transfections
pEGFP-HA-KAP1wt (wild type) and pEGFP-HA-
KAP1S824A were a gift from Y Shiloh (Tel Aviv Univer-
sity, Israel). pEGFP-HA-KAP1S473A and pEGFP-HA-
KAP1S473D were made by site-directed mutagenesis of
pEGFP-HA-KAP1wt using the primers: KAP1-S473A-F,
5’-GAAACGGTCCCGCGCAGGTGAGGGCGAG-3’;
KAP1-S473A-R, 5’-CTCGCCCTCACCTGCGCGGGA
CCGTTTC-3’; KAP1-S473D-F, 5’-GGTGTGAAACGG
TCCCGCGACGGTGAGGGCGAGGTGAGC-3’;K A P 1 -
S473D-R, 5’-GCTCACCTCGCCCTCACCGTCGCGG-
GACCGTTTCACACC-3’.
Plasmid DNA was transfected with FuGENE 6 reagent
(Roche Diagnostics Ltd., Burgess Hill, UK)) following
the manufacturer’s instructions.
Expression and purification of recombinant proteins
pFastBac-TEV-SBP-Chk1wt was prepared by amplifying
Chk1 from pCIneo-FLAG-Chk1 (provided by J Bartek,
Institute of Cancer Biology, Copenhagen, Denmark) and
c l o n i n gi ti n t op F a s t B a c 1 - T E V - S B P( g i f tf r o mPM a r c o -
Casanova, Gurdon Institute, Cambridge, UK) via EcoRI
and XbaI restriction sites. Bacmids were prepared in
DH10Bac™ Escherichia coli cells (Invitrogen, Carlsbad,
CA, USA)) following the manufacturer’s protocol. Pri-
mers for site-directed mutagenesis of Chk1 Leu84 were:
Chk1L84G-F, 5’-GCAATATCCAATATTTATTTGGG-
GAGTACTGTAGTGGAGGAGAGC-3’;C h k 1 L 8 4 G - R ,
5’-GCTCTCCTCCACTACAGTACTCCCCAAATAAA-
TATTGGATATTGC-3’; Chk1L84A-F, 5’-GCAATATC-
CAATATTTATTTGCGGAGTACTGTAGTGGAGGA-
GAGC-3’; and Chk1L84A-R, 5’-GCTCTCCTCCACT
ACAGTACTCCGCAAATAAATATTGGATATTGC-3’.
SBP-tagged wild type and mutated Chk1 proteins were
expressed in Sf9 insect cells and purified to homogeneity
as described for SBP-tag purification [53]. pGEX20T-
Cdc25A was a gift from J Bartek (Institute of Cancer
Biology, Copenhagen, Denmark). GST-Cdc25A was
expressed in BL21 E. coli cells and purified with glu-
tathione sepharose beads following the manufacturer’s
instructions.
Protein kinase assays
All in vitro kinase assays were done in Chk1 kinase buf-
fer (50 mM HEPES, pH 7.4; 13.5 mM MgCl2;a n d1
mM dithiothreitol) in the presence of 1 mM Na3VO4
and 1 mM ATP or ATP analogue. Reactions were incu-
bated for 30 minutes at 30°C and stopped by addition of
1 0m ME D T A ,p H8 .F o rw e s t e r nb l o t t i n g ,p r o t e i n s
were mixed with Laemmli buffer and separated on 9%
SDS-polyacrylamide gels.
Western blotting
Proteins were separated by SDS-PAGE. Antibodies used
were: Chk1 (1:100 mouse G4; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), Chk1 phospho-Ser317
(1:1,000 rabbit; Cell Signaling Technology, Danvers, MA,
USA), Chk1 phospho-Ser345 (1:5,000 rabbit; Cell Signal-
ing), Chk2 phospho-Thr-68 (1:1,000 rabbit; Cell Signal-
ing), Cdc25A (1:100 mouse; Santa Cruz), Cdc25A
phospho-Ser123 was provided by E Appella (National
Cancer Institute, Bethesda,U S ) ,G F P( 1 : 1 , 0 0 0m o u s e ;
Roche), histone H3 phospho-Ser10 (1:5,000 mouse;
A b c a m ,C a m b r i d g e ,U K ) ,K A P 1( 1 : 5 0 0r a b b i t ;S a n t a
Cruz), KAP1 phospho-Ser824 (1:1,000 rabbit; Bethyl
Laboratories, Inc., Montgomery, TX, USA), KAP1 phos-
pho-Ser473 (1:1,000 rabbit; BioLegend), tubulin (1:5,000
mouse; Sigma Aldrich Company, Ltd., Dorset, UK), thio-
phosphate-ester-specific antibody (1:5,000; Epitomics,
Inc., Burlingame, CA, USA) according to the manufac-
turers’ instructions.
Large-scale kinase assay, purification of phospho-
peptides and mass spectrometry
Large-scale Chk1 kinase assay and subsequent peptide
enrichment was as previously described [54]. Briefly, 1
mg of HeLa nuclear extract (Cil Biotech, Mons, Bel-
gium) was incubated with 10 μgo fS B P - C h k 1 L 8 4 Gi n
t h ep r e s e n c eo f1m MN a 3VO4 and 1 mM N6B-ATPgS
in 1× Chk1 kinase buffer for 30 minutes at 30°C. Reac-
tions were stopped by addition of EDTA. Trypsin diges-
tion was done in denaturing buffer following a standard
protocol. Phosphopeptides were enriched using a pre-
viously described method [16]. Briefly, 100 μl of iodoa-
cetyl-agarose beads (SulfoLink gel, Thermo Fisher
Scientific Inc., Rockford, IL, USA) in 100 μl of 50%
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beads were extensively washed with 2 ml each of water,
5 M NaCl, 50% acetonitrile, and 5% formic acid in
water, sequentially. Phosphopeptides were eluted using
200 μl of a 1 mg/ml solution of Oxone, and purified on
C18 StageTips [55]. Phosphopeptides were analyzed on
a linear ion trap/Orbitrap mass spectrometer (LTQ-
Orbitrap XL), as described previously [56]. Raw MS data
were processed using MaxQuant [57]. Data were
searched using the Mascot search engine (Matrix
Science Ltd., London, UK), and peptides were identified
using MaxQuant at a false discovery rate of 1% for pep-
tides and proteins. Cysteine carbamidomethylation was
searched as a fixed modification, whereas amino-term-
inal protein acetylation, phosphorylation of Ser, Thr,
and Tyr, and oxidation of Met were searched as variable
modifications. Raw MS data are available at the Pepti-
deAtlas repository [58].
Cell culture and reagents
U2OS cells were used throughout and grown in
DMEM supplemented with 10% fetal bovine serum,
penicillin, streptomycin, and glutamine. Stable clones
expressing GFP-KAP1 were selected adding G-418 (0.5
mg/ml) to the medium. Aphidicolin, caffeine, etopo-
side, hydroxyurea and camptothecin were from Sigma-
Aldrich; phleomycin was from Melford Laboratories
Ltd., Ipswich, UK. IR was applied with a Faxitron X-
ray cabinet. UV irradiation was done on cells covered
in 1× PBS at a rate of 0.7 J/m
2 per second. AZD7762
w a sp r o v i d e db yA s t r a Z e n e c aa n du s e da t5 0n M .
KU55933 [36] was used at 20 μM. Caffeine was used
at 4 mM. All incubations with inhibitors started 1 h
before any other treatment was applied. N-6-Benzyla-
denosine-5’-O-triphosphate (N6B-ATP) and N-6-ben-
zyladenosine-5’-O-(3-thiotriphosphate) (N6B-ATPgS)
were from BIOLOG Life Science Institute Forschung-
slabor und Biochemica-Vertrieb GmbH, Bremen,
Germany.
siRNAs and transfections
siChk1 and siChk2 were with siGENOME SMARTpool
siRNA (Thermo Fisher Scientific Dharmacon Products,
Lafayette, CO, USA); siLuc (5’-cguacgcggaauacuucgatt-
3’) and siKAP1 [31] were from Eurofins MWG Operon,
Ebersberg, Germany. Transfections were done with
Lipofectamine RNAiMAX (Invitrogen). Cells were trea-
ted 12 h (siChk1 and siChk2) or 48 h (siKAP1)
afterwards.
Immunofluorescence
Cells were grown on poly-L-lysine-coated coverslips,
fixed with 2% paraformaldehyde for 10 minutes and per-
meabilized with 1× PBS containing 0.2% (v/v) Triton X-
1 0 0f o r5m i n u t e s .P r i m a r yantibody staining was for 1
h in 5% fetal bovine serum in 1× PBS with KAP1 phos-
pho-Ser473 (1:100 rabbit; BioLegend) and gH2AX
(1:1,000 mouse; Millipore, Billerica, MA, USA). Second-
ary antibody staining was with goat anti-mouse Alexa
Fluor 488 or goat anti-rabbit Alexa Fluor 594 (1:1,000;
Invitrogen, Carlsbad, CA, USA) for 30 minutes. Cover-
slips were washed three times with 1× PBS and
mounted on slides with Vectashield solution (Vector
Laboratories Ltd., Peterborough, UK) containing 4’,6-
diamidino-2-phenylindole (DAPI) to stain DNA. All
incubations were done at room temperature.
Laser micro-irradiation and cell imaging
For generation of localized damage in cellular DNA by
exposure to a UV-A laser beam [43,59], cells were pla-
ted on glass-bottomed dishes (WillCo Wells B.V.,
Amsterdam, Netherlands) andp r e - s e n s i t i z e dw i t h1 0
μM 5-bromo-2’-deoxyuridine (BrdU; Sigma-Aldrich) in
phenol-red-free medium (Invitrogen) for 24 h at 37°C.
Laser micro-irradiation was done by using a FluoView
1000 confocal microscope (Olympus) equipped with a
37°C heating stage (ibidi GmbH, Martinsried, Germany)
and a 405 nm laser diode (6 mW) focused through a
60× UPlanSApo/1.35 oil objective to yield a spot size of
0.5 to 1 mm. Time of cell exposure to the laser beam
was around 250 ms (fast scanning mode). Laser settings
(0.40 mW output, 50 scans) were chosen that generate a
DDR restricted to the laser path in a pre-sensitization-
dependent manner without noticeable cytotoxicity.
Additional material
Additional file 1: Table S1 - Excel sheet showing a complete list of
identified peptides and phospho-sites. Raw MS data are available at
the PeptideAtlas repository [58].
Additional file 2: Figure S1 - frequencies of amino acids
surrounding phospho-Thr (left panel) or phospho-Ser (right panel)
on peptides containing a basic residue (Arg or Lys) at position -3
identified in our screen. See legend of Figure 2 in main text for details.
Additional file 3: Figure S2 - mutation of KAP1 Ser-473 does not
affect KAP1 SUMOylation. SUMOylated proteins were
immunoprecipitated from U2OS cells expressing RFP-SUMO1 and GFP-
KAP1 versions, and western blots were probed to detect SUMOylated
GFP-KAP1.
Additional file 4: Figure S3 - DNA damage does not affect the
interaction between KAP1 and SETDB1, HDAC1, or MDM2. HEK293
cells were transfected with GFP-KAP1 and treated with 5 μM etoposide
(ETP) for 4 h in the presence or absence of 20 μM KU55933 (ATMi) or 50
nM AZD7762 (AZD). GFP-KAP1 was immunoprecipitated and interaction
with SETDB1, HDAC1, and MDM2 was checked on western blot. KAP1
phospho-Ser473 was used as readout for both DNA-damage induction
and ATM and Chk1/Chk2 inhibition.
Additional file 5: Figure S4 - cell-cycle phosphorylation of KAP1 Ser-
473 is Chk1/Chk2 independent. (a) KAP1 phospho-Ser473 upon serum
addition is insensitive to the Chk1/Chk2 inhibitor AZD7762. RPE-1 cells
were serum-starved for 48 h and then released in medium containing
20% serum for the indicated times in the presence or absence of 50 nM
AZD7762. Chk1 phospho-Ser345 was used as readout for AZD7762. (b)
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DNA damage. RPE-1 cells were treated with 20 Gy ionizing radiation (IR)
and fixed 2 h afterwards. (c) KAP1 Ser473 mutants show no difference
on the interaction with heterochromatin protein 1b (HP1b). Cell extracts
from U2OS cells expressing GFP-KAP1 versions were subjected to pull-
downs with recombinant GST- HP1b. (d) KAP1 phospho-Ser473 does not
preferentially co-localize with heterochromatic regions. Mouse embryonic
fibroblasts were treated as in (b). Heterochromatin is detected as DAPI-
dense regions. gH2AX was used to assess DNA damage.
Additional file 6: Figure S5 - novel Chk1 substrates cluster around
proteins involved in RNA metabolism. Proteins identified in this screen
are labeled in red. A solid line between two proteins indicates a direct
interaction; an arrow indicates that protein A acts on protein B. Protein
clusters were identified using Ingenuity software (Ingenuity Systems, Inc.,
Redwood City, CA, USA).
Additional file 7: Supplementary materials and methods. PDF
describing materials and methods used for Additional files 2 to 6.
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